Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field
| Title: | Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field |
|---|---|
| Authors: | SF Lumley; J Mokaya; TG Maponga; A Kramvis; G Dusheiko; W Irving; M Delphin; K Said Mohammed; LO Downs; E Waddilove; M Anderson; Collins Iwuji; N Msomi; P Ocama; S Hamid; D Adda; R Halford; K Kabagambe; KSM Benschop; S Inzaule; P Chan; MAS Paul; K Izumi; T Nisa; J De Dieu Iragena; A Girón-Callejas; AR Kpossou; G Jamiyu; O Emmanuel; M Balkissa; M Keita; N Prabdial-Sing; A Martinez; EN Magongo; Y Shao; O Sued; LS Sereno; RW Shafer; O Lesi; D Faini; P Easterbrook; C Duncombe; MR Jordan; PC Matthews |
| Publication Year: | 2025 |
| Collection: | University of Sussex (US): Figshare |
| Subject Terms: | Microbiology; Biomedical and clinical sciences; Clinical sciences; Immunology; Medical microbiology; 3207 Medical Microbiology; 32 Biomedical and Clinical Sciences; 3202 Clinical Sciences; Hepatitis - B; HIV/AIDS; Sexually Transmitted Infections; Digestive Diseases; Hepatitis; Infectious Diseases; Liver Disease; Antimicrobial Resistance; 5.1 Pharmaceuticals; 6.1 Pharmaceuticals; Infection; 3 Good Health and Well Being; 3107 Microbiology; 3204 Immunology |
| Description: | In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections. |
| Document Type: | article in journal/newspaper |
| Language: | unknown |
| Relation: | 10779/uos.29545325.v1; https://figshare.com/articles/journal_contribution/Hepatitis_B_virus_resistance_to_nucleos_t_ide_analogue_therapy_WHO_consultation_on_questions_challenges_and_a_roadmap_for_the_field/29545325 |
| Availability: | https://figshare.com/articles/journal_contribution/Hepatitis_B_virus_resistance_to_nucleos_t_ide_analogue_therapy_WHO_consultation_on_questions_challenges_and_a_roadmap_for_the_field/29545325 |
| Rights: | CC BY 4.0 |
| Accession Number: | edsbas.147CF05A |
| Database: | BASE |